标题
CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
作者
关键词
-
出版物
BLOOD
Volume 118, Issue 14, Pages 3922-3931
出版商
American Society of Hematology
发表日期
2011-08-14
DOI
10.1182/blood-2011-01-333138
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport
- (2010) Jean-Yves Wach et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
- (2010) J. J. Wright CLINICAL CANCER RESEARCH
- Anguinomycins and Derivatives: Total Syntheses, Modeling, and Biological Evaluation of the Inhibition of Nucleocytoplasmic Transport
- (2010) Simone Bonazzi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- p53-based Cancer Therapy
- (2010) D. P. Lane et al. Cold Spring Harbor Perspectives in Biology
- Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells
- (2009) T. Hideshima et al. BLOOD
- Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition
- (2009) J. G. Turner et al. CANCER RESEARCH
- Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo
- (2009) S. C. Mutka et al. CANCER RESEARCH
- A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer
- (2009) J.-Y. Yang et al. CLINICAL CANCER RESEARCH
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- Heterocyclic Compounds That Inhibit Rev-RRE Function and Human Immunodeficiency Virus Type 1 Replication
- (2008) D. Shuck-Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure–activity relationship and mechanism of action
- (2008) Tine Van Neck et al. BIOORGANIC & MEDICINAL CHEMISTRY
- CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer
- (2008) Joel Turner et al. CURRENT MEDICINAL CHEMISTRY
- Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation
- (2008) R. K. Kancha et al. HAEMATOLOGICA
- Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways
- (2008) Anwesha Dey et al. NATURE REVIEWS DRUG DISCOVERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started